Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.30 |
| ▸ | POLQ | O75417 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6501986 | 0.92 | HTT (0.36) | MEN1USP2TSHRKMT2AKDM4E | |
| SCHEMBL6506064 | 0.91 | TSHR (0.41) | MEN1USP2TSHRKMT2A | |
| SCHEMBL6504837 | 0.91 | MEN1 (0.32) | MEN1USP2TSHRKMT2AHSD17B10 | |
| SCHEMBL6427691 | 0.91 | ALDH1A1 (0.33) | MEN1USP2TSHRKMT2AGAA | |
| SCHEMBL6501582 | 0.90 | ALDH1A1 (0.35) | KDM4EEPHX2 | |
| SCHEMBL6504717 | 0.89 | MMP2 (0.32) | EPHX2 | |
| SCHEMBL6501771 | 0.84 | CTPS1 (0.38) | — | |
| SCHEMBL6427407 | 0.84 | ALDH1A1 (0.32) | MEN1KMT2AKDM4E | |
| SCHEMBL6426010 | 0.83 | MAPT (0.30) | — | |
| SCHEMBL6508258 | 0.82 | MAP2K1 (0.43) | MEN1USP2TSHRKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | MEN1 979/4885USP2 3037/4885TSHR 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.